clinical development comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
During the period when Germany was divided, the Lower Saxon border crossing at Helmstedt found itself on the main transport artery to West Berlin and, from 1945 to 1990 was the busiest European border crossing point. Of economic significance for the state was the Volkswagen concern, that restarted the production of civilian vehicles in 1945, initially under British management, and in 1949 transferred into the ownership of the newly founded country of West Germany and state of Lower Saxony. Overall, Lower Saxony, with its large tracts of rural countryside and few urban centres, was one of the industrially weaker regions of the federal republic for a long time. In 1960, 20% of the working population worked on the land. In the rest of the federal territory the figure was just 14%. Even in economically prosperous times the jobless totals in Lower Saxony are constantly higher than the federal average. In 1961 Georg Diederichs took office as the minister president of Lower Saxony as the successor to Hinrich Wilhelm Kopf. He was replaced in 1970 by Alfred Kubel. The arguments about the Gorleben Nuclear Waste Repository, that began during the time in office of minister president Ernst Albrecht (1976–1990), have played an important role in state and federal politics since the end of the 1970s. In 1990 Gerhard Schröder entered the office of minister-president. On 1 June 1993, the new Lower Saxon constitution entered force, replacing the "Provisional Lower Saxon Constitution" of 1951.
Context-sensitive half-life or context sensitive half-time is defined as the time taken for blood plasma concentration of a drug to decline by one half after an infusion designed to maintain a steady state (i.e. a constant plasma concentration) has been stopped. The "context" is the duration of infusion. When a drug which has a multicompartmental pharmacokinetic model is given by intravenous infusion it initially will distribute to the central compartment and then move out of this compartment into one or two peripheral compartments. Once this infusion is discontinued, drug continues to move into the peripheral compartments until an equilibrium is reached. At this time, the only way drug may leave plasma is by metabolism or excretion. As the plasma concentration falls, the concentration gradient of drug reverses and drug moves from peripheral compartments back into plasma, maintaining the plasma concentration of the drug, often prolonging the pharmacological effect. If an infusion has reached steady state then the context-sensitive half-life is equal to the terminal plasma half-life of the drug. Otherwise it will be shorter than the terminal elimination half-life. Remifentanil is relatively context insensitive whilst fentanyl and thiopentone are examples of drugs which have significant context-sensitive changes in their half-life. The Context-Sensitive Half-Time describes the time required for the plasma drug concentration to decline by 50% after terminating an infusion of a particular duration.
is the consumption rate of A, a reactant. This is equal to the rate expression A is involved in. The rate expression is often related to the fractional conversion both through the consumption of A and through any k changes through temperature changes that are dependent on conversion.
Human (and other eukaryote) cells can produce ATP from glucose without oxygen in a process called glycolysis. This is not as efficient as respiration, but provides a high instantaneous output, and is hence used by some muscle cells. Glycolysis consumes ADP, Pi, glucose, and NAD+ to produce ATP, pyruvate, and NADH. Through lactate fermentation, pyruvate and NADH are turned into lactate and NAD+, thereby regenerating the NAD+ required for more glycolysis. During the 1990s, the lactic acid hypothesis was created to explain why people experienced burning or muscle cramps that occurred during and after intense exercise. The hypothesis proposes that a lack of oxygen in muscle cells results in a switch from cellular respiration to fermentation. Lactic acid created as a byproduct of fermentation of pyruvate from glycolysis accumulates in muscles causing a burning sensation and cramps. Research from 2006 has suggested that acidosis isn't the main cause of muscle cramps. Instead cramps may be due to a lack of potassium in muscles, leading to contractions under high stress. Animals, in fact, do not produce lactic acid during fermentation. Despite the common use of the term lactic acid in the literature, the byproduct of fermentation in animal cells is lactate. Another change to the lactic acid hypothesis is that when sodium lactate is inside of the body, there is a higher period of exhaustion in the host after a period of exercise.
As a result of protests by Akwesasne residents on their rights to cross the border unimpeded, as provided under the 1795 Jay Treaty, the Canada Border Services Agency closed its post on Cornwall Island, instead requiring travellers to proceed to the checkpoint in the city of Cornwall. As a consequence of the arrangement, residents of the island are required to clear border controls when proceeding North to the Ontario mainland, as well as when proceeding South to Akwesasne territory in New York, thereby constituting internal controls from both a Canadian and an Akwesasne perspective. Similarly, travelling between Canada and the Quebec portion of the Akwesasne nation requires driving through the state of New York, meaning individuals must clear American controls when leaving Quebec proper and Canadian border controls when entering Quebec proper. However, Canada does not impose border controls when entering the Quebec portion of the Akwesasne Nation. Nevertheless, for residents who assert a Haudenosaunee national identity distinct from Canadian or American citizenship, the intricate network of Canadian and American border controls is seen as a foreign-imposed system of internal border controls, similar to the Israeli checkpoints in Palestinian territory. The city of Hyder, Alaska, has also been subject to internal border controls since America chose to stop regulating arrivals in Hyder from British Columbia.
Sources: en.wikipedia.org
origin of replication (ORI) Also replication origin or simply origin. A particular location within a DNA molecule at which DNA replication is initiated. Origins are usually defined by the presence of a particular replicator sequence or by specific chromatin patterns.
== History == Flupirtine was discovered and developed between the 1970s and the 1990s by Chemiewerk Homburg in Frankfurt am Main, Germany, which became Degussa Pharma Group and then through mergers, ASTA Pharma and Asta Medica. Retigabine, a bioisostere of flupirtine, was discovered as part of the same program and has a similar mechanism of action. Flupirtine was approved for the treatment of pain in 1984 in Europe under the brand name Katadolon. As of 2013 it was used in 11 member countries: Bulgaria, Estonia, Germany, Hungary, Italy, Latvia, Lithuania, Poland, Portugal, Romania and Slovak Republic. Many generics entered the European market around 2011. It was never introduced to the United States market for any indication but in 2008, Adeona Pharmaceuticals, Inc. (now called Synthetic Biologics, Inc.) obtained an option to license issued and patent pending applications relating to flupirtine's use in the treatment of ophthalmic indications, particularly retinitis pigmentosa. As of 2016 it is marketed under many brand names, including Efiret, Flupigil, Flupirtin, Flupirtina, Flupirtine, Flupizen, Fluproxy, Katadolon, Metanor, Trancolong, and Zentiva.
Parathyroid hormone is efficiently removed from the blood by a receptor-mediated process in the liver and is broken down into smaller peptide fragments. The fragments derived from the amino-terminus are further degraded within the cell while the fragments derived from the carboxy-terminus are released back into the blood and cleared by the kidney. These carboxy-terminal fragments are thought to play a role in the regulation of parathyroid hormone activity. Under normal physiological conditions full-length parathyroid hormone H constitutes only 5-30% of the circulating forms of the molecule, while 70-95% is present as carboxy-terminal fragments. Following administration of Preotact, carboxy-terminal fragments make up about 60-90% of the circulating forms of the molecule. Intersubject variability in systemic clearance is about 15%.
== Landmark designations == Bryant Park and the New York Public Library Main Branch were jointly listed on the National Register of Historic Places (NRHP) in 1966. Its listing on the NRHP is distinct from the "New York Public Library" on the same day, which covered just the main branch building. In addition, in 1974, the New York City Landmarks Preservation Commission designated the park as a New York City scenic landmark.
== Distribution == Nolina lindheimeriana is endemic just to the Edwards Plateau region of western central Texas in the USA. The species has been reported in Zacatecas state, Mexico, well outside the distribution area usually designated, and various online sources report its presence there. Sources for the information in the citation just given do not mention its presence in Zacatecas. Searching for online herbarium collections of Nolina lindheimeriana on file at UNAM (MEXU), the National Autonomous University of Mexico, returns only collections from Texas.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.